FIG. 4.

Potentiation of CD95L promoter activity by simultaneously applied anticancer drugs. Hep3B cells were transiently transfected with the −36/+100 CD95L promoter construct. Cells were treated for 48 h with 1.7 μM etoposide (eto) or 100 μg of 5-FU/ml or both agents, as indicated. Cells were lysed, and luciferase activity was measured. Three experiments with similar outcomes were performed. Transfection efficiencies were monitored by cotransfection of a Renilla luciferase construct driven from a basal promoter.